From: Impact of AKAP6 polymorphisms on Glioma susceptibility and prognosis
SNP ID | Models | OR (95%CI) | p | OR (95%CI) | p |
---|---|---|---|---|---|
Age | ≤ 40 | > 40 | |||
rs2239647 | Allele | 1.20 (0.92–1.57) | 0.171 | 1.17 (0.89–1.54) | 0.273 |
Homozygote(AA) | 1.68 (0.87–3.24) | 0.123 | 2.60 (1.23–5.51) | 0.012 | |
Heterozygote(CA) | 1.19 (0.83–1.71) | 0.347 | 0.82 (0.57–1.18) | 0.281 | |
Dominant | 1.26 (0.89–1.78) | 0.187 | 0.98 (0.70–1.39) | 0.925 | |
Recessive | 1.56 (0.82–2.95) | 0.174 | 2.83 (1.36–5.89) | 0.006 | |
Additive | 1.25 (0.95–1.64) | 0.107 | 1.17 (0.89–1.54) | 0.254 | |
Gender | Male | Female | |||
rs2145587 | Allele | 1.06 (0.84–1.33) | 0.633 | 1.28 (0.98–1.68) | 0.065 |
Homozygote(AA) | 1.16 (0.71–1.90) | 0.553 | 1.40 (0.77–2.53) | 0.266 | |
Heterozygote(CA) | 1.00 (0.70–1.43) | 0.998 | 1.62 (1.10–2.38) | 0.016 | |
Dominant | 1.04 (0.74–1.45) | 0.837 | 1.57 (1.08–2.27) | 0.017 | |
Recessive | 1.16 (0.74–1.82) | 0.514 | 1.08 (0.62–1.87) | 0.794 | |
Additive | 1.06 (0.84–1.34) | 0.625 | 1.30 (0.99–1.71) | 0.060 | |
rs2239647 | Allele | 1.22 (0.94–1.58) | 0.130 | 1.14 (0.86–1.51) | 0.374 |
Homozygote(AA) | 2.42 (1.21–4.87) | 0.003 | 1.48 (0.75–2.89) | 0.256 | |
Heterozygote(GA) | 0.94 (0.67–1.32) | 0.714 | 1.02 (0.70–1.50) | 0.909 | |
Dominant | 1.08 (0.78–1.50) | 0.627 | 1.09 (0.76–1.57) | 0.630 | |
Recessive | 2.49 (1.25–4.93) | 0.009 | 1.46 (0.76–2.80) | 0.253 | |
Additive | 1.22 (0.94–1.57) | 0.135 | 1.13 (0.86–1.50) | 0.384 | |
Classification | Astroglioma patients VS Healthy controls | ||||
rs2239647 | Allele | 1.18 (0.96–1.45) | 0.106 | ||
Homozygote(AA) | 1.90 (1.15–3.15) | 0.012 | |||
Heterozygote(CA) | 0.98 (0.75–1.29) | 0.900 | |||
Dominant | 1.10 (0.85–1.42) | 0.485 | |||
Recessive | 1.92 (1.17–3.13) | 0.009 | |||
Additive | 1.19 (0.97–1.45) | 0.098 |